Patents Assigned to Canadian Blood Services
-
Patent number: 11090288Abstract: The present disclosure relates to a compound of formula or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.Type: GrantFiled: September 25, 2018Date of Patent: August 17, 2021Assignees: UNIVERSITY HEALTH NETWORK, CANADIAN BLOOD SERVICESInventors: Donald R. Branch, Lakshmi P. Kotra
-
Patent number: 11007221Abstract: This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.Type: GrantFiled: December 13, 2013Date of Patent: May 18, 2021Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10494634Abstract: The present disclosure concerns aptamers of formula (I) capable of specifically binding to Factor XIa. The aptamers can be used to prevent, treat or alleviate the symptoms of thrombosis. The aptamers can also be used to detect Factor XIa in a sample and/or purify Factor XIa from a sample. The aptamers can further be used to identity putative therapeutic agents for the prevention, treatment or alleviation of symptoms associated with thrombosis.Type: GrantFiled: May 4, 2017Date of Patent: December 3, 2019Assignee: CANADIAN BLOOD SERVICESInventors: William Peter Sheffield, David Apraku Donkor
-
Patent number: 10188681Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population. The non-proliferative allogeneic leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition with the latter leukocyte population. Cellular-based preparations and processes for achieving cellular therapy are also provided.Type: GrantFiled: July 12, 2013Date of Patent: January 29, 2019Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10130609Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.Type: GrantFiled: March 12, 2014Date of Patent: November 20, 2018Assignees: UNIVERSITY HEALTH NETWORK, CANADIAN BLOOD SERVICESInventors: Donald R. Branch, Lakshmi P. Kotra
-
Publication number: 20180305453Abstract: The present disclosure relates to monovalent antibodies and chimeric proteins (comprising the monovalent antibodies) for the treatment of an auto-immune inflammatory disorder or condition. The monovalent antibody moiety lacks a Fc region, is specific for an activating Fc receptor and is for limiting or avoiding the activation of an immune cell induced in the presence and upon the binding of a ligand of the activating Fc receptor to the activating Fc receptor. The monovalent antibodies and chimeric proteins are especially useful for the prevention, treatment or alleviation of symptoms associated with an auto-immune inflammatory disorder caused or maintained by the engagement of an auto-antibody having a Fc region capable of engaging the activating Fc receptor to mediate the pathological destructions of cells or tissues.Type: ApplicationFiled: October 20, 2016Publication date: October 25, 2018Applicant: Canadian Blood ServicesInventors: Alan H. Lazarus, Xiaojie Yu, William Peter Sheffield
-
Patent number: 10039788Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.Type: GrantFiled: July 12, 2013Date of Patent: August 7, 2018Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10039787Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.Type: GrantFiled: July 12, 2013Date of Patent: August 7, 2018Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10039786Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.Type: GrantFiled: July 12, 2013Date of Patent: August 7, 2018Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 9579367Abstract: The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.Type: GrantFiled: June 12, 2014Date of Patent: February 28, 2017Assignee: Canadian Blood ServicesInventor: Ed Pryzdial
-
Publication number: 20160206655Abstract: This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.Type: ApplicationFiled: December 13, 2013Publication date: July 21, 2016Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. SCOTT, Duncheng WANG, Wendy M. TOYOFUKU
-
Patent number: 9134336Abstract: The described apparatus for analyzing a biological sample includes a first analysis instrument fluidly connected to a reservoir for receiving a first flow of the biological fluid and adapted for performing a measurement of a property of the biological sample. A second analysis instrument is fluidly connected to the reservoir for receiving a second flow of the biological fluid and adapted for performing a thermally controlled analysis of the biological sample. The second analysis instrument includes a thermally controlled chamber. A flow stopping device stops the second flow within the thermally controlled chamber in order to allow the second analysis instrument to perform the thermally controlled analysis of the biological sample. The first analysis instrument may include, for example, a hematology analyzer or a flow cytometer, and the second analysis instrument may include, for example, a dynamic light scattering instrument.Type: GrantFiled: August 31, 2010Date of Patent: September 15, 2015Assignee: Canadian Blood ServicesInventors: Elisabeth Maurer, Long Hin Fong
-
Patent number: 9134206Abstract: A deformable container (5) containing a fluid product to be tested includes a flexible outer wall (10) enclosing a main cavity (9) therein for holding the fluid product and at least one appendix (14) for containing a sample volume to be tested. The appendix is displaceable from a first position, wherein the appendix is invaginated within a periphery of the deformable container, and a second position, wherein the appendix protrudes outwardly from the outer wall and defines a second cavity (7) therein for a sample fluid volume, such as to permit testing of the sample volume within the appendix (14). The appendix is displaced into the second position by the fluid product within the deformable container when pressure is applied to the outer wall to force the sample volume of the fluid product from the main cavity of the deformable container into the second cavity of the appendix.Type: GrantFiled: August 31, 2011Date of Patent: September 15, 2015Assignee: Canadian Blood ServicesInventor: Elisabeth Maurer
-
Publication number: 20150196597Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.Type: ApplicationFiled: July 12, 2013Publication date: July 16, 2015Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20150174168Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.Type: ApplicationFiled: July 12, 2013Publication date: June 25, 2015Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20150164948Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.Type: ApplicationFiled: July 12, 2013Publication date: June 18, 2015Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20140329319Abstract: A device and method for polymer modification of biological cells includes pumping a first liquid mixture comprising biological cells from a first reservoir to a mixing chamber and a second liquid mixture comprising activated polymer from a second reservoir to the same mixing chamber, independently controlling an output volume of the first and second liquid mixtures pumped into the mixing chamber using at least one pump, mixing the first and second liquid mixtures in the mixing chamber to produce a final mixture comprising polymer-modified biological cells, and evacuating the final mixture comprising polymer-modified biological cells from the mixing chamber into an output reservoir.Type: ApplicationFiled: May 2, 2013Publication date: November 6, 2014Applicant: CANADIAN BLOOD SERVICESInventor: CANADIAN BLOOD SERVICES
-
Patent number: 8877458Abstract: Methods of detecting bacterial contamination in a platelet concentrate are performed using a dynamic light scattering (DLS) instrument and a sample holder. A sample of platelet concentrate can be held vertically or horizontally in a capillary in the sample holder. Alternatively, novel platelet storage bags modified to include an optically translucent window can be held within another variant of the sample holder. Still alternatively, platelet storage bags having one or more tubes detachably appended to the bag can be used. A sample is drawn off into an appended tube for placement directly into the sample holder. This method provides a number of related, non-invasive techniques for detecting whether bacteria has contaminated a platelet concentrate. Contamination indicators include a population of particles different from platelets, microparticles or proteins, bad-quality platelets, i.e. low DLS score, and very high or very low scattering intensity.Type: GrantFiled: February 1, 2008Date of Patent: November 4, 2014Assignee: Canadian Blood ServicesInventor: Elisabeth Maurer
-
Patent number: 8835129Abstract: A method of diagnosing a pathological condition by detecting microparticles in a sample of bodily fluid using dynamic light scattering (DLS) is disclosed. The detection of microparticles in the bodily fluid by DLS may be used as an indicator of existing disease, to evaluate a risk of disease, as well, as to monitor the efficacy of a treatment for disease.Type: GrantFiled: December 3, 2012Date of Patent: September 16, 2014Assignee: Canadian Blood ServicesInventor: Elisabeth Maurer
-
Publication number: 20140213481Abstract: RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kpa/b, Fya/b, FY0, Jka/b, Dia/b, and HPA-1a/b.Type: ApplicationFiled: April 8, 2014Publication date: July 31, 2014Applicant: Canadian Blood ServicesInventor: Gregory A. Denomme